Questions on the Order Paper  With regard to those fatalities and serious adverse events (SAEs) associated with Pfizer's and Moderna's COVID-19 mRNA-based vaccines and tracked by Health Canada (HC) and the Public Health Agency of Canada (PHAC): (a) did HC or the PHAC or any other federal agency or entity or agency contracted by the federal government detect a safety signal when examining, (i) the VAERS data from the USA, (ii) the EudraVigilance data from Europe, (iii) the Yellow Card data from England; (b) if the answer to (a) is affirmative for either (i), (ii) or (iii), what are the safety issues and how is the federal government addressing them; (c) what are the respective provincial numbers of vaccine-associated fatal and non­fatal heart attacks, strokes and other cardiovascular events recorded in Canada's vaccine surveillance program(s), between December 31, 2020 and December 31, 2023; (d) given the data from (c), has HC, the PHAC, or another federal government body such as the Canadian Institute for Health Information (CIHI) undertaken the research to determine if there has been an increase in the events described in (c) compared with their baseline values prior to the COVID-19 vaccine roll-outs; (e) what does the temporal association between the fatal or non-fatal serious adverse events in (c) and the timing of the mRNA­based vaccine roll-outs (primary series and boosters) show, per age group; (f) has the submission of any provincial health agencies' reports of vaccine-associated fatalities been denied by Canada's vaccine surveillance program(s); (g) if the answer to (f) is affirmative, how many reports of fatalities were denied by Canada's vaccine surveillance program(s) and for what reasons; (h) how many fatalities and SAEs associated with any drug or medical devices removes that item from the market; (i) how many fatalities and SAEs associated the mRNA-based vaccines will be deemed sufficient, as a threshold safety signal, to shut down the distribution of the mRNA products and what agency has established this benchmark; and (j) in consideration of cumulative reports of fatalities and SAEs during Pfizer's 3-month post-marketing phase, and in Canada and other jurisdictions around the world associated with the mRNA products, why was this vaccination program permitted to continue and who made that decision?

Questions Passed as Orders for Returns  With regard to the review by Health Canada (HC), the Public Health Agency of Canada (PHAC), or the National Advisory Committee on Immunization, of a pre-print study posted on October 15, 2023 of which six authors are associated with the US Food and Drug Administration that found "a new signal was detected for seizures-convulsions after BNT162b2 (2-4 years) and mRNA1273 COVID-19 vaccinations (2-5 years),": (a) which federal health agency, organization, committee or department(s) or outsourced contracted firm is responsible for reviewing or identifying studies such as the pre-print titled "Safety of Monovalent BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and NVX-CoV2373 (Novavax) COVID- 19 Vaccines in US Children Aged six months to 17 years;"; (b) has any federal health agency, organization, committee, department(s) or outsourced contracted firm reviewed or been made aware of the forementioned study or learned about the new safety signal of seizures/convulsions among children following monovalent COVID-19 vaccine; (c) if the answer to (b) is affirmative, has HC or any federal health agency, organization or committee issued any statement to the Canadian public or any communication to the provinces or the medical community to create awareness of this new safety signal; (d) if the answer to (c) is affirmative, what was the statement or communication provided; (e) if the answer to (c) is negative, why not; (f) how many episodes of seizures-convulsions have been reported in children under 17 years in Canadian Adverse Events following Immunization Surveillance System records, from (i) May 1, 2021 to April 30, 2023, (ii) May 1, 2018 to April 30, 2020; (g) what provincial and territory data is the federal government relying upon to monitor risk of seizures and convulsions in this cohort in real time; (h) how far out is the government monitoring this data (e.g. 28 days post-vaccine, up to 3 months, 6 months, 12 months, beyond 12 months post-COVID-19 immunization); (i) what are the Canadian government's threshold values for marking the likelihood of a vaccine serious adverse event as transitioning from an extremely rare, to a rare occurrence, and from a rare to a common occurrence; (j) what is the threshold whereby a safety signal of seizures or convulsions would shut down the mRNA vaccine program in children under the age of 17 years; (k) why are children's seizures-convulsions not listed on HC's webpage denoted to children's side-effects which was last updated on October 27, 2023; (l) with real-time monitoring, what other safety signals has HC, the PHAC or any other federal agency or department discovered post-mRNA vaccine injection for (i) children under age 5 years, (ii) children 6-17 years, (iii) persons 18-25 years, (iv) persons 26-35 years; (m) is HC receiving any data directly from provincial datasets to monitor increased usage of provincial health systems by Canadian children post-vaccination; (n) has any federal health agency or entity such as the Canadian Institute for Health Information or outsourced contractor tracked the number of episodes of myocarditis and pericarditis in young persons under the age of 35, post-vaccination, using billing or ICD-10 data from physicians and hospitals across Canada both before and after the COVID-19 injections had commenced; (o) if the answer to (n) is affirmative, (i) for what period of time post-immunization are they tracked, (ii) is the rate of myocarditis and pericarditis in persons under 35 years following the roll-out of the COVID-19 mRNA vaccines greater or less than the baseline rates of myocarditis and pericarditis from 2016-2019; (p) if there were deviations from the baseline found in (o)(ii), by how much did this occur and by which method has the determination of any difference, or lack thereof, been made; (q) if the answer to (n) is negative, why is this data not being tracked; and (r) when examining the risk-of-harm to benefit ratio of the COVID-19 mRNA products and when considering the combination of serious adverse events such as seizures-convulsions, myocarditis and pericarditis in young persons, what is the combined threshold of serious adverse events by which mRNA products would no longer be available to (i) children under the age of 5 years, (ii) children 6-17 years old, (iii) persons 18-25 years old, (iv) persons 26-35 years old, and who determines these thresholds, when, and based on what data?

Budget Implementation Act, 2024, No. 1  Mr. Speaker, I know there is very little good to talk about in this Bill C-69, this budget implementation act, but it would be nice if the member could use some of his time at least to talk about the actual issue we are debating.

Framework on the Access to and Use of Cash Act  moved for leave to introduce Bill C-400, An Act to establish a framework for the continued access to and use of cash in Canada and to make related amendments to other Acts. Mr. Speaker, it is my honour and privilege to rise today to table a bill calling for a framework on the access to and the use of cash.

Business of Supply  Madam Speaker, I am sure it is, because I did a quick calculation with my calculator—

Petitions  Mr. Speaker, I rise to present a petition on behalf of many Canadians who are concerned about human rights protections in India. The petitioners say that according to the United States Commission on International Religious Freedom, various actors are supporting and enforcing sectarian policies seeking to establish India as a Hindu state.

Canada-Newfoundland and Labrador Atlantic Accord Implementation Act  Madam Speaker, I rise on a bit of a point of order. I indicated earlier that I would be supporting Bill C-49 in my speech. I support the amendment, but I will not necessarily be supporting the bill.

Canada-Newfoundland and Labrador Atlantic Accord Implementation Act  Madam Speaker, I thank the member for Edmonton West for bringing that to the attention of the House and Canadians this evening, who are probably engrossed in watching the proceedings here tonight. I know that pretty soon they are going to be flipping over to the Edmonton game. We are going to all be cheering hard for our Canadian team, and our Canadian team is going to win.

Canada-Newfoundland and Labrador Atlantic Accord Implementation Act  Madam Speaker, we, including the Conservatives, in good faith sent the bill to committee for study. In good faith we brought in witnesses, and we listened to witnesses provided by the government and by the other opposition parties, expecting that at the end of the day, based on witness testimony, the government would consider amendments brought forward to improve the piece of legislation, because we did all want to see it move forward.

Canada-Newfoundland and Labrador Atlantic Accord Implementation Act  Madam Speaker, the member for Skeena—Bulkley Valley was right. Almost all of my speech was critical of Bill C-49. It was intentionally that way because there is a lot to criticize. At the end of the day, I made it very clear that we would be supporting the legislation, but there is a lot of opportunity to improve it.

Canada-Newfoundland and Labrador Atlantic Accord Implementation Act  Madam Speaker, I was delighted when I heard the member for Waterloo express her jubilation on the floor of the House that we would be supporting this bill. I thought it was very appropriate for her to do that. On the issue of constitutionality, Bill C-69 has been found wanting.

Canada-Newfoundland and Labrador Atlantic Accord Implementation Act  Madam Speaker, what thrills me the most about the member's asking me the question is that he actually listened to my speech. He was actually impacted by what I said and he actually conceded that Canada contributes only 1.5% to global emissions. He went further to say that we are one of the highest per capita contributors to emissions.

Canada-Newfoundland and Labrador Atlantic Accord Implementation Act  Madam Speaker, it is a privilege to rise in the House and speak to Bill C-49, an act to amend the Canada-Newfoundland and Labrador Atlantic Accord Implementation Act and the Canada-Nova Scotia Offshore Petroleum Resources Accord Implementation Act, which also makes consequential amendments to other acts.

Petitions  Madam Speaker, I am pleased to present a petition from my constituents from the communities of Emerson-Franklin and Springfield, as well as the towns of Niverville and Kleefeld. The petitioners want to highlight to the House that volunteer firefighters account for 71% of Canada's total firefighting essential first responders.

Petitions  Mr. Speaker, these petitioners wish to present an issue to the House. They are seeking to support the health and safety of Canadian firearms owners. The petitioners recognize the importance of owning firearms, but they are concerned about the impacts of hearing loss caused by the damaging noise levels of firearms and the need for noise reduction.